{
    "2021-11-21": [
        [
            {
                "time": "2021-11-21",
                "original_text": "基石药业-B：与恒瑞医药就CS1002达成在大中华地区的战略合作",
                "features": {
                    "keywords": [
                        "基石药业",
                        "恒瑞医药",
                        "CS1002",
                        "战略合作",
                        "大中华地区"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-11-21",
                "original_text": "恒瑞医药携手基石药业布局重磅肿瘤药",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "基石药业",
                        "肿瘤药",
                        "布局"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-11-21",
                "original_text": "“药茅”又一大动作！斥巨资引进抗肿瘤药品",
                "features": {
                    "keywords": [
                        "药茅",
                        "恒瑞医药",
                        "抗肿瘤药品",
                        "引进"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-11-21",
                "original_text": "2亿美金！基石药业与恒瑞医药强强联合，就抗CTLA-4单抗CS1002达成战略合作！",
                "features": {
                    "keywords": [
                        "2亿美金",
                        "基石药业",
                        "恒瑞医药",
                        "CTLA-4",
                        "单抗",
                        "战略合作"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-11-21",
                "original_text": "恒瑞医药引进基石药业抗CTLA-4单克隆抗体CS1002",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "基石药业",
                        "CTLA-4",
                        "单克隆抗体",
                        "引进"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-11-21",
                "original_text": "国金证券：维持恒瑞医药“买入”评级 与基石合作 加速创新转型",
                "features": {
                    "keywords": [
                        "国金证券",
                        "恒瑞医药",
                        "买入评级",
                        "基石合作",
                        "创新转型"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}